Brazilian Dermatology Market Second Largest in the World Behind the United States
PETALUMA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of regulatory approvals by the Brazilian Ministério da Saúde for seven of Sonoma’s non-steroidal and non-antibiotic topical dermatology products:
Gramaderm® Hydrogel – intended as a skin cleanser after treatment of mild to moderate acne.
Gramaderm® – intended as a skin cleanser in a hydrogel vehicle after treatment of mild to moderate acne.
Epicyn™ – intended as a scar treatment.
Pediacyn™ – intended as an atopic dermatitis treatment.
Pediacyn™ Gel – intended as an atopic dermatitis treatment in a gel vehicle.
Lasercyn™ – intended as a skin cleanser following cosmetic procedures such as laser skin resurfacing.
Lasercyn™ Hydrogel – intended as a skin cleanser in a hydrogel vehicle following cosmetic procedures such as laser skin resurfacing.
“My Brazilian counterparts now have treatment options that can either replace or complement the standard protocols. In my practice I use Sonoma’s products for healing and as a steroid-sparing agent, anti-pruritic and anti-inflammatory,” said Dr. Miriam Bettencourt, assistant clinical professor of dermatology at the University of Nevada and adjunct professor of dermatology at Touro University in Las Vegas. “Having studied medicine in Brazil and with many of my colleagues practicing dermatology in Brazil, Sonoma’s new approvals should provide additional non-steroidal and non-antibiotic alternatives much like I use in here in the United States.”
Sonoma Pharmaceuticals is currently seeking to partner with a Brazilian healthcare company relative to licensing these newly approved products in the Brazilian dermatology space.
“We see the Brazilian dermatology market as being highly lucrative in terms of ongoing ramping revenue,” said Bruce Thornton, Sonoma’s VP of international sales. “Brazilian dermatologists are cutting edge when it comes to general dermatology and aesthetic procedures, and the addition of seven new hypochlorous acid-based products provides new alternatives for physicians worried about the side effects of topical steroids and resistance issues with the overuse of antibiotics.”
About the Brazilian Dermatology Market
According to BCC Research, skin conditions are among the most common health problems in most national populations, collectively exceeding the prevalence of conditions such as obesity, hypertension and cancer. The considerable costs of skin diseases include physician visits, hospital care, prescription drugs and over-the-counter products for treating or managing these conditions, as well as indirect costs due to productivity losses.
The global market for skin disease treatment technologies is estimated to reach $20.4 billion in 2020. The U.S market is the largest segment and should reach $8.6 billion in 2020. The BRIC (Brazil, Russia, India, China) countries are the fastest growing region of the global dermatology market and should total more than $4.6 billion by 2020.
AI
